AR037331A1 - Compuestos derivados de 1,2,4-tiadiazol sustituidos, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones - Google Patents
Compuestos derivados de 1,2,4-tiadiazol sustituidos, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composicionesInfo
- Publication number
- AR037331A1 AR037331A1 ARP020104272A ARP020104272A AR037331A1 AR 037331 A1 AR037331 A1 AR 037331A1 AR P020104272 A ARP020104272 A AR P020104272A AR P020104272 A ARP020104272 A AR P020104272A AR 037331 A1 AR037331 A1 AR 037331A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- heterocycloalkyl
- heteroaryl
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 15
- 125000003545 alkoxy group Chemical group 0.000 abstract 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000003282 alkyl amino group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 201000004700 rosacea Diseases 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical class C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010050337 Cerumen impaction Diseases 0.000 abstract 1
- 208000001840 Dandruff Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010013786 Dry skin Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 102000004378 Melanocortin Receptors Human genes 0.000 abstract 1
- 108090000950 Melanocortin Receptors Proteins 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 206010072139 Ocular rosacea Diseases 0.000 abstract 1
- 241001303601 Rosacea Species 0.000 abstract 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 210000002939 cerumen Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- 210000004907 gland Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 210000004175 meibomian gland Anatomy 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 208000020469 nerve plexus disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000006380 plexopathy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33792701P | 2001-11-08 | 2001-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037331A1 true AR037331A1 (es) | 2004-11-03 |
Family
ID=23322615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104272A AR037331A1 (es) | 2001-11-08 | 2002-11-07 | Compuestos derivados de 1,2,4-tiadiazol sustituidos, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7049331B2 (enExample) |
| EP (1) | EP1446394B1 (enExample) |
| JP (1) | JP4436676B2 (enExample) |
| CN (1) | CN1312139C (enExample) |
| AR (1) | AR037331A1 (enExample) |
| AT (1) | ATE344254T1 (enExample) |
| AU (1) | AU2009201842B2 (enExample) |
| BR (1) | BR0214024A (enExample) |
| CA (1) | CA2466140C (enExample) |
| CY (1) | CY1105907T1 (enExample) |
| DE (1) | DE60215848T2 (enExample) |
| DK (1) | DK1446394T3 (enExample) |
| ES (1) | ES2275918T3 (enExample) |
| IL (1) | IL161829A (enExample) |
| MX (1) | MXPA04004458A (enExample) |
| MY (1) | MY134993A (enExample) |
| NO (1) | NO328195B1 (enExample) |
| NZ (1) | NZ532883A (enExample) |
| PT (1) | PT1446394E (enExample) |
| RS (1) | RS51530B (enExample) |
| RU (1) | RU2317292C2 (enExample) |
| SG (1) | SG176310A1 (enExample) |
| SI (1) | SI1446394T1 (enExample) |
| TW (1) | TWI328586B (enExample) |
| WO (1) | WO2003040117A1 (enExample) |
| ZA (1) | ZA200404484B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| JP2005504043A (ja) | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| NZ532883A (en) * | 2001-11-08 | 2007-09-28 | Ortho Mcneil Pharm Inc | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| WO2005054849A2 (en) * | 2003-12-06 | 2005-06-16 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor mc5 (mc5r) |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| NZ550114A (en) | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| BRPI0518241A (pt) | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| US7704533B2 (en) * | 2006-12-13 | 2010-04-27 | J&J Consumer Companies, Inc. | Compositions and methods of inducing hair growth utilizing Continus coggygria |
| EP2101806B1 (en) * | 2006-12-14 | 2013-05-01 | NeuroNova AB | Treatment of parkinson's disease or parkinsonian disorders using agents that decrease the activity of the melanocortin 4 receptor |
| RU2348623C1 (ru) * | 2007-05-21 | 2009-03-10 | Государственное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ИГХТУ) | Способ получения 3,5-диамино-1,2,4-тиадиазола |
| US8247453B2 (en) * | 2008-02-21 | 2012-08-21 | Janssen Pharmaceutica, Nv | Methods for the treatment of dermatological disorders |
| US8008291B2 (en) | 2008-02-29 | 2011-08-30 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
| US8377925B2 (en) | 2008-02-29 | 2013-02-19 | Mimetica Pty Ltd | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor |
| US8343958B2 (en) | 2008-02-29 | 2013-01-01 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists |
| JP2012501334A (ja) | 2008-08-29 | 2012-01-19 | トランス テック ファーマ，インコーポレイテッド | 置換アミノチアゾール誘導体、医薬組成物、および使用の方法 |
| JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
| JP2012524814A (ja) * | 2009-04-24 | 2012-10-18 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−チアジアゾール誘導体の安定的な局所組成物 |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| ES2360783B1 (es) * | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
| US8470880B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Methods of reducing hair loss and/or facilitating hair growth and/or regrowth |
| US8470833B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Hair growth and/or regrowth compositions |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| WO2014031732A2 (en) * | 2012-08-22 | 2014-02-27 | Cornell University | Methods for inhibiting fascin |
| US8962041B2 (en) | 2013-02-12 | 2015-02-24 | Johnson & Johnson Consumer Companies, Inc. | Methods and compositions for enhancing hair quality using blackberry extract |
| CN106232583B (zh) | 2014-02-20 | 2020-04-24 | 康奈尔大学 | 用于抑制肌成束蛋白的化合物和方法 |
| WO2019241755A2 (en) * | 2018-06-15 | 2019-12-19 | Jay Dela Cruz | Treatment of synucleinopathy and animal models of synucleinopathy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE131373C (enExample) | ||||
| JPS6011481A (ja) | 1983-06-30 | 1985-01-21 | Nippon Soda Co Ltd | １，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤 |
| JPH02173165A (ja) | 1988-12-27 | 1990-07-04 | Nippon Soda Co Ltd | 防汚剤 |
| TR199903082T2 (xx) * | 1997-06-24 | 2000-07-21 | Janssen Pharmaceutica N.V. | Anjiogenez inhibit�r� 5-s�bstit�e-1,2,4,-tiadiazolil t�revleri. |
| US6127381A (en) | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| EP1076648B1 (de) | 1998-04-29 | 2006-07-12 | MERCK PATENT GmbH | Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten |
| US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| WO2000024725A1 (en) | 1998-10-26 | 2000-05-04 | Vertex Pharmaceuticals Incorporated | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase |
| WO2001055107A2 (en) * | 2000-01-28 | 2001-08-02 | Melacure Therapeutics Ab | Aromatic amines and amides acting on the melanocortin receptors |
| NZ532883A (en) * | 2001-11-08 | 2007-09-28 | Ortho Mcneil Pharm Inc | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
-
2002
- 2002-11-04 NZ NZ532883A patent/NZ532883A/en not_active IP Right Cessation
- 2002-11-04 ES ES02776448T patent/ES2275918T3/es not_active Expired - Lifetime
- 2002-11-04 WO PCT/US2002/035340 patent/WO2003040117A1/en not_active Ceased
- 2002-11-04 RU RU2004114214/04A patent/RU2317292C2/ru not_active IP Right Cessation
- 2002-11-04 SG SG2006034359A patent/SG176310A1/en unknown
- 2002-11-04 CN CNB028268547A patent/CN1312139C/zh not_active Expired - Fee Related
- 2002-11-04 SI SI200230459T patent/SI1446394T1/sl unknown
- 2002-11-04 US US10/287,095 patent/US7049331B2/en not_active Expired - Fee Related
- 2002-11-04 CA CA2466140A patent/CA2466140C/en not_active Expired - Fee Related
- 2002-11-04 AT AT02776448T patent/ATE344254T1/de active
- 2002-11-04 EP EP02776448A patent/EP1446394B1/en not_active Expired - Lifetime
- 2002-11-04 PT PT02776448T patent/PT1446394E/pt unknown
- 2002-11-04 JP JP2003542163A patent/JP4436676B2/ja not_active Expired - Fee Related
- 2002-11-04 RS YUP-397/04A patent/RS51530B/sr unknown
- 2002-11-04 DK DK02776448T patent/DK1446394T3/da active
- 2002-11-04 MX MXPA04004458A patent/MXPA04004458A/es active IP Right Grant
- 2002-11-04 BR BR0214024-1A patent/BR0214024A/pt active Search and Examination
- 2002-11-04 DE DE60215848T patent/DE60215848T2/de not_active Expired - Lifetime
- 2002-11-07 AR ARP020104272A patent/AR037331A1/es not_active Application Discontinuation
- 2002-11-08 MY MYPI20024179A patent/MY134993A/en unknown
- 2002-11-08 TW TW091133320A patent/TWI328586B/zh not_active IP Right Cessation
-
2004
- 2004-05-06 IL IL161829A patent/IL161829A/en not_active IP Right Cessation
- 2004-06-07 ZA ZA2004/04484A patent/ZA200404484B/en unknown
- 2004-06-07 NO NO20042372A patent/NO328195B1/no not_active IP Right Cessation
-
2006
- 2006-02-01 US US11/344,772 patent/US7375123B2/en not_active Expired - Fee Related
-
2007
- 2007-01-08 CY CY20071100017T patent/CY1105907T1/el unknown
-
2009
- 2009-05-08 AU AU2009201842A patent/AU2009201842B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037331A1 (es) | Compuestos derivados de 1,2,4-tiadiazol sustituidos, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones | |
| AR037284A1 (es) | Compuestos derivados de 1,2,4-tiadiazol-2-io, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones | |
| CO2022002781A2 (es) | Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos | |
| MA57825B1 (fr) | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques | |
| EP4520328A3 (en) | Heterocyclic compounds as immunomodulators | |
| DK1474406T3 (da) | Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider | |
| MA50667A (fr) | Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif | |
| GT200300075AA (es) | Compuestos que modulan la actividad ppar y procedimientos para su preparacion (patente fraccionaria no. 1 de la solicitud no. pi-20030075) | |
| UY37606A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| NO20044882L (no) | Acyl-4-karboksylfenylurinstoffderivater, deres fremstilling og anvendelse | |
| NO20074390L (no) | Forsterket bimatoprost oye-opplosning | |
| AR063211A1 (es) | Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide. | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CL2009000953A1 (es) | Compuestos derivados de 2-imino-3-metil-pirrolo pirimidinona, composicion farmaceutica, util para inhibir la beta-secretasa, destinado al tratamiento de la enfermedad de alzheimer, sindrome de down, parkinson, perdida de la memoria, demencia, accidente cerebrovascular, microgliosis e inflamacion cerebral, glaucoma amiloidosis, diabetes tipo ii, entre otras. | |
| NO20070176L (no) | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| CR20210544A (es) | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| WO2006084176A3 (en) | Compounds and compositions as ppar modulators | |
| NO20065926L (no) | Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav | |
| CL2011001839A1 (es) | Compuestos derivados de tiadiazoles y oxadiazoles, inhibidores de la biosintesis de trigliceridos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de obesidad, dislipidemia, afecciones de alteracion de la glucosa en ayunas, diabetes de tipo 2, entre otras. | |
| WO2020165839A9 (en) | Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| BRPI0514735B8 (pt) | derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |